Prognostic Value of C-reactive Protein Levels in Patients with Bone Neoplasms: A Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Apr 19

PMID 29668751

Citations 14

Authors

Wenyi Li

Xujun Luo

Zhongyue Liu

Yanqiao Chen

Zhihong Li

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to conduct a meta-analysis of retrospective studies that investigated the association of preoperative C-reactive protein (CRP) levels with the overall survival (OS) of patients with bone neoplasms.

Methods: A detailed literature search was performed in the Cochrane Library, Web of Science, Embase and PubMed databases up to August 28, 2017, for related research publications written in English. We extracted the data from these studies and combined the hazard ratios (HR) and 95% confidence intervals (CIs) to assess the correlation between CRP levels and OS in patients with bone neoplasms.

Results: Five studies with a total of 816 participants from several countries were enrolled in this current meta-analysis. In a pooled analysis of all the publications, increased serum CRP levels had an adverse prognostic effect on the overall survival of patients with bone neoplasms. However, the combined data showed no significant relationship between the level of CRP and OS in Asian patients (HR = 1.73; 95% CI: 0.86-3.49; P = 0.125). Similar trends were observed in patients with bone neoplasms when stratified by ethnicity, histology, metastasis and study sample size.

Conclusions: The results of this meta-analysis suggest that increased CRP expression indicates a poorer prognosis in patients with bone neoplasms. More prospective studies are needed to confirm the prognostic significance of CRP levels in patients with bone neoplasms.

Citing Articles

C-Reactive Protein Pretreatment-Level Evaluation with Histopathological Correlation for Chondrosarcoma Prognosis Assessment-A 15-Year Retrospective Single-Center Study.

Consalvo S, Hinterwimmer F, Stephan M, Breden S, Lenze U, Peeken J Diagnostics (Basel). 2024; 14(13).

PMID: 39001318 PMC: 11241698. DOI: 10.3390/diagnostics14131428.

Prognostic role of C-reactive protein in patients with endometrial cancer: a meta-analysis.

Yu X, Zhang X Biomark Med. 2024; 18(6):279-289.

PMID: 38639733 PMC: 11216499. DOI: 10.2217/bmm-2023-0810.

C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.

Mouliou D Diseases. 2023; 11(4).

PMID: 37873776 PMC: 10594506. DOI: 10.3390/diseases11040132.

Prognostic significance of C-reactive protein in patients with cervical cancer: a meta-analysis.

Yang S, Zhang Z, Shen L Front Oncol. 2023; 13:1232409.

PMID: 37731642 PMC: 10507700. DOI: 10.3389/fonc.2023.1232409.

Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis.

Xu Y, Ma K, Zhang F, Ma M, Hong L, Wang J Exp Ther Med. 2023; 26(2):361.

PMID: 37408861 PMC: 10318603. DOI: 10.3892/etm.2023.12060.

References

Nozoe T, Saeki H, Sugimachi K . Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001; 182(2):197-201. DOI: 10.1016/s0002-9610(01)00684-5. View

Gakis G, Todenhofer T, Renninger M, Schilling D, Sievert K, Schwentner C . Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. 2011; 108(11):1800-5. DOI: 10.1111/j.1464-410X.2011.10234.x. View

Zhou F, Zhou L, Guo T, Wang N, Hao H, Zhou Y . Plasma proteomics reveals coagulation, inflammation, and metabolic shifts in H-type hypertension patients with and without acute ischemic stroke. Oncotarget. 2017; 8(59):100384-100395. PMC: 5725028. DOI: 10.18632/oncotarget.22233. View

Lamb G, McMillan D, Ramsey S, Aitchison M . The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer. 2006; 94(6):781-4. PMC: 3216422. DOI: 10.1038/sj.bjc.6603034. View

Liu B, Huang Y, Sun Y, Zhang J, Yao Y, Shen Z . Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep. 2016; 6:39862. PMC: 5180218. DOI: 10.1038/srep39862. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Morris-Stiff G, Gomez D, Prasad K . C-reactive protein in liver cancer surgery. Eur J Surg Oncol. 2008; 34(7):727-9. DOI: 10.1016/j.ejso.2008.01.016. View

Alifano M, Falcoz P, Seegers V, Roche N, Schussler O, Younes M . Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2011; 142(5):1161-7. DOI: 10.1016/j.jtcvs.2011.07.021. View

Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T . Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res. 2012; 32(8):3535-8. View

10.

Qian B . Inflammation fires up cancer metastasis. Semin Cancer Biol. 2017; 47:170-176. DOI: 10.1016/j.semcancer.2017.08.006. View

11.

Heikkila K, Ebrahim S, Lawlor D . A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007; 61(9):824-33. PMC: 2703800. DOI: 10.1136/jech.2006.051292. View

12.

Muir K, Weir C, Alwan W, Squire I, Lees K . C-reactive protein and outcome after ischemic stroke. Stroke. 1999; 30(5):981-5. DOI: 10.1161/01.str.30.5.981. View

13.

Gockel I, Dirksen K, Messow C, Junginger T . Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol. 2006; 12(23):3746-50. PMC: 4087469. DOI: 10.3748/wjg.v12.i23.3746. View

14.

Ridker P, Glynn R, Hennekens C . C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998; 97(20):2007-11. DOI: 10.1161/01.cir.97.20.2007. View

15.

Prins R, Rademacher B, Mongoue-Tchokote S, Alumkal J, Graff J, Eilers K . C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol. 2010; 30(1):33-7. PMC: 2894303. DOI: 10.1016/j.urolonc.2009.11.012. View

16.

Sanchez-Salcedo P, de-Torres J, Martinez-Urbistondo D, Gonzalez-Gutierrez J, Berto J, Campo A . The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development. Lung Cancer. 2016; 97:28-34. DOI: 10.1016/j.lungcan.2016.04.010. View

17.

Evola F, Costarella L, Pavone V, Caff G, Cannavo L, Sessa A . Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. Front Pharmacol. 2017; 8:150. PMC: 5383728. DOI: 10.3389/fphar.2017.00150. View

18.

Kinoshita A, Onoda H, Takano K, Imai N, Saeki C, Fushiya N . Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol. 2012; 29(4):2800-8. DOI: 10.1007/s12032-012-0220-1. View

19.

Shao N, Cai Q . High pretreatment serum C-reactive protein level predicts a poor prognosis for combined small-cell lung cancer. Tumour Biol. 2015; 36(11):8465-70. DOI: 10.1007/s13277-015-3611-z. View

20.

Elinav E, Nowarski R, Thaiss C, Hu B, Jin C, Flavell R . Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013; 13(11):759-71. DOI: 10.1038/nrc3611. View